Characteristics of Allogeneic Blood Stem Cell Recipients
| Number | 160 |
| Median age (range) | 40 yrs (17-61) |
| Sex (Male/Female) | 91/69 |
| Diagnosis | |
| Acute lymphoblastic leukemia | 12 |
| Acute myelogenous leukemia | 36 |
| Chronic lymphocytic leukemia | 7 |
| Chronic myelogenous leukemia | 23 |
| Chronic myeloproliferative disorder | 1 |
| Hodgkin’s disease | 4 |
| Malignant lymphoma | 54 |
| Multiple myeloma | 3 |
| Myelodysplastic syndrome | 7 |
| Solid tumor | 13 |
| Disease status | |
| First remission or chronic phase | 12 |
| Second remission or accelerated phase | 31 |
| Relapse or blast crisis | 117 |
| Preparative regimen | |
| Total body irradiation-based | 33 |
| Busulfan-based | 91 |
| Other | 36 |
| Graft-versus-host disease prophylaxis | |
| CSA/methylprednisolone | 50 |
| FK506/methylprednisolone | 55 |
| FK506/methotrexate | 55 |
| Number | 160 |
| Median age (range) | 40 yrs (17-61) |
| Sex (Male/Female) | 91/69 |
| Diagnosis | |
| Acute lymphoblastic leukemia | 12 |
| Acute myelogenous leukemia | 36 |
| Chronic lymphocytic leukemia | 7 |
| Chronic myelogenous leukemia | 23 |
| Chronic myeloproliferative disorder | 1 |
| Hodgkin’s disease | 4 |
| Malignant lymphoma | 54 |
| Multiple myeloma | 3 |
| Myelodysplastic syndrome | 7 |
| Solid tumor | 13 |
| Disease status | |
| First remission or chronic phase | 12 |
| Second remission or accelerated phase | 31 |
| Relapse or blast crisis | 117 |
| Preparative regimen | |
| Total body irradiation-based | 33 |
| Busulfan-based | 91 |
| Other | 36 |
| Graft-versus-host disease prophylaxis | |
| CSA/methylprednisolone | 50 |
| FK506/methylprednisolone | 55 |
| FK506/methotrexate | 55 |